Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avanos Medical ( (AVNS) ) has provided an announcement.
On January 13, 2026, Avanos Medical planned to showcase its strategy and growth outlook at the JP Morgan Healthcare Conference, highlighting its investment rationale, portfolio mix and pipeline in specialty nutrition and pain management and recovery. Management outlined above-market growth ambitions for its U.S. specialty nutrition segment, supported by #1 domestic positions in long-term, short-term and neonatal feeding, an expanded innovation pipeline and the 2025 acquisition of Nexus Medical and its TKO anti-reflux connector, while projecting at-market growth for pain management, emphasizing non-opioid surgical pain relief and radiofrequency ablation offerings, and signaling that the newly appointed CEO is focused on executing strategic imperatives and deploying a strong balance sheet and M&A pipeline to drive future expansion.
The most recent analyst rating on (AVNS) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on Avanos Medical stock, see the AVNS Stock Forecast page.
Spark’s Take on AVNS Stock
According to Spark, TipRanks’ AI Analyst, AVNS is a Neutral.
Avanos Medical’s overall stock score reflects significant profitability challenges and weak technical indicators. While the earnings call provided some positive guidance and strategic initiatives, the negative valuation metrics and bearish technical analysis weigh heavily on the score. The company’s ability to improve operational efficiencies and profitability will be crucial for future performance.
To see Spark’s full report on AVNS stock, click here.
More about Avanos Medical
Avanos Medical is a medical technology company focused on specialty nutrition systems and pain management and recovery solutions, offering enteral feeding products for long-term, short-term and neonatal patients as well as non-opioid post-operative pain pumps, radiofrequency ablation systems and cold compression therapy devices. The company holds leading U.S. market positions across its core nutrition portfolios, operates a global direct sales organization, employs more than 2,200 people across manufacturing sites in the U.S., Canada and Mexico, and maintains a strong balance sheet with leverage below 0.5x and net sales of $690–$700 million targeted at mid-single-digit organic growth.
Average Trading Volume: 518,089
Technical Sentiment Signal: Sell
Current Market Cap: $573.3M
Learn more about AVNS stock on TipRanks’ Stock Analysis page.